|
|
|
|
|
Highlights from the 2024 ASCO Genitourinary Cancers Symposium |
|
|
|
|
| Population-Based Trends in Intravesical Gemcitabine Use Among Patients with High-Risk Non-Muscle Invasive Bladder Cancer
|
| Stephen Williams, MD, MS
|
| Stephen Williams presented a retrospective cohort study on population-based trends in intravesical gemcitabine use among patients with high-risk NMIBC. The study, conducted using SEER-Medicare data, revealed a significant increase in the use of intravesical gemcitabine since 2019 in patients with high-risk NMIBC. However, the analysis also highlighted suboptimal treatment duration, with a majority of patients discontinuing therapy within four months.
|
|
|
|
|
|
| Reasons for Refusal of or Ineligibility for Radical Cystectomy in Patients with BCG–Unresponsive High-Risk NMIBC from the SunRISe-1 Study
|
| Joseph Jacob, MD
|
| Joseph Jacob presented findings on the reasons for refusal of or ineligibility for radical cystectomy in patients with BCG–unresponsive high-risk NMIBC from the SunRISe-1 study. The study investigated patients enrolled in the TAR-200 monotherapy cohort of SunRISe-1, a phase 2b trial evaluating the efficacy and safety of TAR-200, a novel intravesical drug delivery system, in patients with BCG-unresponsive high-risk NMIBC who were ineligible for or refused radical cystectomy.
|
|
|
|
|
|
| RC48-ADC Versus BCG in Adjuvant Treatment of High-Risk Non-Muscle Invasive Bladder Cancer with HER2 Over-Expression: A Real-World Retrospective Study
|
| Haoyang Liu, MD
|
| Haoyang Liu presented real-world results from a study assessing RC48-ADC versus BCG in the adjuvant treatment of high-risk NMIBC with HER2 over-expression. The 12-month recurrence-free survival rate was 100% for RC48-ADC and 57.6% for BCG. RC48-ADC demonstrated promising efficacy with a manageable safety profile, suggesting it may be an alternative adjuvant therapy for BCG in terms of the 12-month recurrence-free survival rate.
|
|
|
|
|
|
| Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NIMBC and Quantifies Molecular Response to Nadofaragene Firadenovec
|
| Vikram M. Narayan, MD
|
| Vikram Narayan presented a study on urinary minimal residual disease detection predicting recurrence in BCG-unresponsive non-muscle-invasive bladder cancer (NIMBC) and assessing molecular response to nadofaragene firadenovec. The study suggests that urinary minimal residual disease assessment could support stratification in future treatment trials and enable quantitative evaluation of molecular response to drug treatment.
|
|
|
|
|
|
| Punch: Preliminary Results from a Phase II Study of Intra‑arterial Chemotherapy Combined with Tislelizumab and BCG in High-Risk Non-Muscle-Invasive Bladder Cancer
|
| Zongren Wang, MD
|
| Zongren Wang presented preliminary results from the Punch phase II study, which evaluated the efficacy and safety of intra‑arterial chemotherapy combined with tislelizumab and BCG as a bladder-preserving treatment for high-risk non-muscle-invasive bladder cancer patients.
|
|
|
|
|
|
| INVEST: A Phase Ib Window of Opportunity Study of Atezolizumab Administered Either Intravesically or Direct Tumor Injection in Patients with Bladder Cancer Prior to Radical Cystectomy
|
| Syed A. Hussain, MBBS, MSc, MD, FRCP
|
| Syed Hussain presented the trial design of INVEST, a phase Ib window of opportunity study of atezolizumab administered either intravesically or through direct tumor injection in patients with bladder cancer prior to radical cystectomy. The study aims to investigate the safety and preliminary activity of intravesical atezolizumab, delivered either passively or through direct injection into the tumor or bladder wall, in patients awaiting radical cystectomy for urothelial cell carcinoma of the bladder.
|
|
|
|
|
|
|
|
|
|
|
| AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma Versus Observation
|
| Andrea B. Apolo, MD
|
| Andrea Apolo presented the AMBASSADOR Alliance A031501 study, a phase III randomized adjuvant trial comparing pembrolizumab to observation in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery. The study demonstrated a statistically significant and clinically meaningful improvement in disease-free survival with adjuvant pembrolizumab, regardless of PD-L1 status.
|
|
|
|
|
|
| Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression |
| Bishoy Faltas, MD |
| Bishoy Faltas presented an artificial intelligence-based multimodal deep learning model aiming to predict pathologic complete response (pCR) to neoadjuvant chemotherapy in muscle-invasive bladder cancer. The model integrated histopathology, cell types, and gene expression data from the SWOG S1314-COXEN trial, demonstrating improved pCR prediction when combining all three branches. |
|
|
|
|
|
| Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints with Other Therapy |
| William Y. Kim, MD |
| William Kim discussed the biological basis of pairing and sequencing checkpoints with other therapies in the context of advanced urothelial carcinoma. He highlighted the heterogeneity of the tumor microenvironment in bladder cancer metastases and the impact of prior therapies on remodeling the tumor microenvironment. Dr. Kim emphasized the importance of understanding spatial biology and the heterogeneous nature of the tumor microenvironment in muscle-invasive bladder cancer. |
|
|
|
|
|
| Infigratinib vs Placebo in Patients with Resected Urothelial Cancer Bearing FGFR3 Mutation or Fusion: Primary DFS Analysis from the Phase 3, Randomized PROOF302 Study |
| Sumanta K. Pal, MD, FASCO |
| Monty Pal presented the primary disease-free survival analysis from the PROOF302 phase 3 randomized study, which assessed infigratinib versus placebo in patients with resected urothelial cancer harboring FGFR3 mutations or fusions. No significant differences were observed in disease-free survival, metastasis-free survival, or overall survival between the infigratinib and placebo arms. |
|
|
|
|
|
|
|
|
|
|
| Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD-1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations
|
| Rohit K. Jain, MD
|
| Rohit Jain presented a phase Ib trial evaluating the combination of erdafitinib and enfortumab vedotin in patients with metastatic urothelial carcinoma harboring somatic FGFR2/3 genetic alterations who have progressed after platinum-based chemotherapy and/or PD1/L1 inhibitor therapies.
|
|
|
|
|
|
| Sequencing of Erdafitinib and Enfortumab Vedotin in Patients with FGFR2/3 Altered Advanced Urothelial Cancer: Analysis of UNITE Database
|
| Cindy Y. Jiang, MD |
| Cindy Jiang presented an analysis of the UNITE database, evaluating the sequencing of erdafitinib and enfortumab vedotin in patients with fibroblast growth factor receptor (FGFR2/3) altered advanced urothelial cancer. The analysis showed no significant difference in overall survival between the two treatment sequences. However, overall survival for both sequences was superior to enfortumab vedotin alone. |
|
|
|
|
|
| Application of Artificial Intelligence Features of Nuclear Morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy |
| Shilpa Gupta, MD |
| Shilpa Gupta presented the application of artificial intelligence features of nuclear morphology from the BLASST-1 trial, which evaluated neoadjuvant nivolumab with gemcitabine-cisplatin for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy. The study utilized a computerized artificial intelligence model to analyze nuclear morphologic and architectural features on pre-treatment transurethral resection of bladder tumor (TURBT) tissues. |
|
|
|
|
|
| Avelumab First-Line Maintenance Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: Results from the Real-World US PATRIOT-II Study
|
| Petros Grivas, MD, Ph.D.
|
| Petros Grivas presented results from the US PATRIOT-II study, a real-world analysis of avelumab first-line maintenance therapy in patients with locally advanced/metastatic urothelial carcinoma who were progression-free after first-line platinum-based chemotherapy. The study demonstrated real-world overall survival and progression-free survival outcomes consistent with the JAVELIN Bladder 100 trial.
|
|
|
|
|
|
|
